Apollo Hospitals Stock: Citi Sees 33% Upside to Rs 9,600

Introduction

Global brokerage firm Citi has reiterated its 'high-conviction buy' rating on Apollo Hospitals Enterprise Ltd., raising its target price to a street-high of Rs 9,600 per share. This new target suggests a potential upside of approximately 33% from its recent closing price of around Rs 7,220. Citi's optimistic outlook is based on the stock's attractive valuation following a recent correction, which the firm believes has more than accounted for near-term operational headwinds.

Citi's Bullish Rationale

Citi's confidence in Apollo Hospitals is rooted in several key factors. The primary argument is that the stock's valuation has become compelling, trading below its historical average and at a discount to its peers. The brokerage believes that concerns such as temporary disruptions in patient flow from Bangladesh and initial losses from newly commissioned hospitals are already priced into the current stock value. This improved risk-reward profile makes the stock an attractive investment at current levels. Looking forward, Citi projects a robust consolidated EBITDA compound annual growth rate (CAGR) of 23% between FY25 and FY28, driven by the scaling up of new facilities and growth in its digital health segment.

Strong Financial Performance

The company's recent financial results support this positive outlook. In the third quarter, Apollo Hospitals reported a strong operational performance with a consolidated revenue of Rs 6,500 crore, marking a 17% year-on-year increase. Its EBITDA for the same period stood at Rs 970 crore, a significant 27% rise from the previous year. This growth was primarily led by the core hospitals business, which saw a 15% revenue increase even as new capacities were being added. Hospital EBITDA margins also improved by 60 basis points year-on-year to 24.5%.

Growth Drivers: Hospitals and HealthCo

Apollo's growth strategy is twofold, focusing on its core hospital business and the rapidly expanding HealthCo segment. The hospital division continues to show strong earnings visibility with mid-teens revenue growth, supported by expansion in Tier-1 cities, stable occupancy rates, and a richer case mix driving higher average revenue per occupied bed (ARPOB).

Simultaneously, the Apollo HealthCo segment is transitioning from a cost center to a value creator. This shift is driven by scaling up offline pharmacies, narrowing losses in the Apollo 24/7 digital platform, and the eventual merger with Keimed. Management expects Apollo 24/7 to achieve EBITDA break-even by the end of FY26, transforming the digital business into a significant contributor to profitability.

Navigating Near-Term Headwinds

While the long-term outlook is strong, Citi acknowledges near-term challenges. The commissioning of new hospitals is expected to result in initial losses of around Rs 200 crore over FY26-27. This could keep hospital EBITDA margins relatively flat at approximately 24% in the short term. However, as these new facilities ramp up operations and achieve higher occupancy, Citi anticipates a margin expansion of over 100 basis points in FY28.

Divergent Views from Analysts

While Citi is highly optimistic, other brokerage firms hold more varied opinions, reflecting different assessments of the company's short-term challenges and long-term potential. Morgan Stanley maintains an 'Overweight' rating with a target of Rs 8,813. In contrast, ICICI Securities has downgraded the stock to 'HOLD' with a revised target of Rs 8,080. Despite these differences, the overall sentiment remains positive, with a majority of the 26 analysts covering the stock maintaining a 'Buy' recommendation.

Stock Performance and Market Position

Apollo Hospitals' stock has delivered mixed returns recently. While it has gained about 5% in the last month, its performance over three and six months has been nearly flat. Over a one-year period, the stock has provided a return of approximately 20%. The share price is currently trading between its 52-week high of Rs 8,099 and a 52-week low of Rs 6,002.15. With a market capitalization of around Rs 1,08,899 crore, it remains a dominant player in the Indian healthcare sector.

Future Outlook and Expansion Plans

Apollo Hospitals is actively pursuing an aggressive expansion strategy. The company plans to add approximately 1,600 beds over the next 14 months and a total of 3,577 beds over the next three to four years. This expansion includes new hospitals in Pune and Kolkata. Management has reiterated its guidance for the HealthCo and Keimed merged entity, targeting a combined revenue of Rs 250 billion with a 24% CAGR over FY25-27, supported by break-even in the digital business and margin improvements.

Conclusion

Citi's upgraded target price for Apollo Hospitals highlights a strong conviction in the company's long-term growth trajectory. The brokerage believes that current market concerns are temporary and already reflected in the stock's attractive valuation. While investors will need to weigh the near-term margin pressures against the robust expansion plans and the promising evolution of the HealthCo business, the underlying fundamentals and strong financial performance present a compelling investment case for the healthcare giant.